CoChat

Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: Arandomized, placebo‐controlled, double‐blind, parallel‐group study

Frandsen, Christian S., Dejgaard, Thomas F., Andersen, Henrik U., Holst, Jens J., Hartmann, Bolette, Thorsteinsson, Birger, Madsbad, Sten · 2017 · Diabetes, Obesity and Metabolism
Cited by 40

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Aim: Glucagon‐like peptide‐1 receptor agonist ( GLP‐1RA ) therapy is a potential treatment as adjunct to insulin in type 1 diabetes ( T1D ). However, GLP‐1RAs inhibit glucagon secretion and delay the gastric emptying ( GE ) rate and may impair recovery from hypoglycaemia. We evaluated the effect of the GLP‐1RA liraglutide on counterregulatory responses and GE rate during hypoglycaemia in persons with T1D . Materials and methods: In a 12‐week, randomized, double‐blind, placebo‐controlled study, 20 patients aged >18 years with T1D and HbA1c ≥8% (64 mmol/mol) were randomly assigned (1:1) to liraglutide 1.2 mg once daily or placebo as add‐on to insulin treatment. Before and at end of treatment a hypoglycaemic clamp (plasma glucose target 2.5 mmol/ L ) was carried out, followed by a liquid meal. Primary endpoint was change in GE rate (evaluated by area under the paracetamol curve and time to peak). Secondary endpoints included changes in glycaemic recovery, counter‐regulatory hormones, pancreatic polypeptide ( PP ), GLP ‐1, blood pressure and heart rate. Results: During the period J une 2013 to O ctober 2014, 20 patients were enrolled. After 12 weeks of treatment, changes in GE rates did not differ significantly between groups ( P = .96), with no significant changes from baseline, whether evaluated from AUCs or time to peak. The secondary endpoints, glycaemic recovery, counter‐regulatory hormone responses, systolic blood pressure and GLP ‐1 and PP responses, were also similar. Heart rate increased with liraglutide from 69 ± 4 to 80 ± 5 beats/min ( P = .02). Conclusions: Liraglutide does not compromise glycaemic recovery, GE rate or counter‐regulatory hormone responses in T1D patients during hypoglycaemia. No treatment‐related safety issues were identified.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12830

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

Metadata

Authors
Frandsen, C. S., Dejgaard, T. F., Andersen, H. U., Holst, J. J., Hartmann, B., Thorsteinsson, B., & Madsbad, S.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2017-03-17
Volume
19
Issue
6
Pages
773-782
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2549197160
Cited by
40
References
17
FWCI
3.75
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.